Peer Review Congress #PRC10: In 2014-23 China experienced rapid growth in RCTs, surpassing Japan & the US. Neoplastic, CV, metabolic disease accounted for the largest percentages, each representing ~15-25% of all registered trials. In the US, mental health trials increased, reflecting growing interest in the area.

In 2014-23 China experienced rapid growth in RCTs, surpassing Japan & the US. Neoplastic, CV, metabolic disease accounted for the largest percentages, each representing ~15-25% of all registered trials. In the US, mental health trials increased, reflecting growing interest in the area.